TEMOZOLOMIDE IN PATIENTS WITH GEM OR AA TUMORS AT FIRST RELAPSE

替莫唑胺治疗首次复发的宝石型或AA型肿瘤患者

• 批准号: 6244296
• 负责人: ALEXANDER M SPENCE
• 金额: $ 2.42万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-10 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244296
• 关键词: antineoplastics; clinical research; drug administration rate /duration; drug screening /evaluation; glioblastoma multiforme; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; oral administration; procarbazine

To determine the efficacy of Temozolomide defined as progression-free survival at 6 months and safety of Temozolomide when administered orally, once a day for 5 days repeated every 28 days in the treatment of patients with GBM (Glioblastoma Multiforme) or AA (Anaplastic Astrocytoma) at first relapse. A reference agent procarbazine is included in the study of patients with GBM to verify that objective responses can be obtained using the reference agent.

确定Temozolomide的疗效定义为无进展 在6个月的生存和口服替莫唑胺的安全性， 每天一次每28天重复一次，患者每28天重复一次 首先与GBM（胶质母细胞瘤多形）或AA（偏长胶质细胞瘤）一起使用 复发。 参考剂pracarbazine包括 具有GBM的患者可以使用 参考代理。